PREDICTORS OF PREMATURE WITHDRAWAL AND DOSE REDUCTIONS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) PLUS RIBAVIRIN IN A LARGE, MULTINATIONAL, OPEN-LABEL EXPANDED ACCESS PROGRAM